MENU
+Compare
DSGN
Stock ticker: NASDAQ
AS OF
Apr 16 closing price
Price
$3.38
Change
+$0.06 (+1.81%)
Capitalization
191.86M

DSGN Design Therapeutics Forecast, Technical & Fundamental Analysis

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations... Show more

DSGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for DSGN with price predictions
Apr 15, 2025

DSGN in +14.88% Uptrend, advancing for three consecutive days on April 15, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DSGN advanced for three days, in of 233 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DSGN's RSI Indicator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 53 cases where DSGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

DSGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DSGN as a result. In of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for DSGN turned negative on March 20, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at .

DSGN moved below its 50-day moving average on March 25, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for DSGN crossed bearishly below the 50-day moving average on March 26, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for DSGN moved below the 200-day moving average on March 11, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DSGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for DSGN entered a downward trend on April 15, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. DSGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.792) is normal, around the industry mean (13.447). P/E Ratio (0.000) is within average values for comparable stocks, (63.350). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.767). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (251.155).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DSGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
DSGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

DSGN is expected to report earnings to rise 18.75% to -28 cents per share on May 12

Design Therapeutics DSGN Stock Earnings Reports
Q1'25
Est.
$-0.28
Q4'24
Beat
by $0.02
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.02
Q1'24
Beat
by $0.06
The last earnings report on March 10 showed earnings per share of -23 cents, beating the estimate of -25 cents. With 105.11K shares outstanding, the current market capitalization sits at 191.86M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
6005 Hidden Valley Road
Phone
+1 858 293-4900
Employees
124
Web
https://www.designtx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BMCRX22.00N/A
N/A
BlackRock Advantage Large Cap Gr R
HQIVX20.04N/A
N/A
Hartford Equity Income R6
GIDAX7.37N/A
N/A
Goldman Sachs Intl Eq Div & Prem A
LVPIX100.12N/A
N/A
ProFunds Large Cap Value Inv
JDVZX15.00N/A
N/A
JPMorgan Diversified R6

DSGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DSGN has been loosely correlated with VRDN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DSGN jumps, then VRDN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DSGN
1D Price
Change %
DSGN100%
+2.15%
VRDN - DSGN
43%
Loosely correlated
-3.76%
KRYS - DSGN
41%
Loosely correlated
+0.13%
COGT - DSGN
40%
Loosely correlated
+6.33%
MDGL - DSGN
38%
Loosely correlated
-0.38%
RCKT - DSGN
38%
Loosely correlated
+10.49%
More